Sunrest Lifescience Ltd
Incorporated in 2017, Sunrest Lifescience Ltd trades in Health care and Cosmetics products[1]
- Market Cap ₹ 29.2 Cr.
- Current Price ₹ 34.0
- High / Low ₹ 54.4 / 26.4
- Stock P/E 9.44
- Book Value ₹ 22.4
- Dividend Yield 0.00 %
- ROCE 18.1 %
- ROE 17.4 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.8% over last 3 years.
- Company has high debtors of 204 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 10.64 | 15.79 | 24.60 | 24.64 | 29.48 | 33.12 | 33.26 | |
| 10.49 | 15.51 | 23.49 | 21.74 | 28.57 | 30.12 | 28.44 | |
| Operating Profit | 0.15 | 0.28 | 1.11 | 2.90 | 0.91 | 3.00 | 4.82 |
| OPM % | 1.41% | 1.77% | 4.51% | 11.77% | 3.09% | 9.06% | 14.49% |
| 0.00 | 0.00 | 0.02 | 0.03 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.01 | 0.02 | 0.06 | 0.22 | 0.30 | 0.51 |
| Depreciation | 0.02 | 0.04 | 0.06 | 0.13 | 0.10 | 0.09 | 0.23 |
| Profit before tax | 0.13 | 0.23 | 1.05 | 2.74 | 0.59 | 2.61 | 4.08 |
| Tax % | 76.92% | 21.74% | 25.71% | 25.55% | 61.02% | 23.37% | 24.26% |
| 0.04 | 0.17 | 0.78 | 2.04 | 0.23 | 2.00 | 3.09 | |
| EPS in Rs | 3.40 | 0.27 | 2.33 | 3.60 | |||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 11% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 79% |
| 3 Years: | 15% |
| TTM: | 55% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 13% |
| Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 3.00 | 4.29 | 4.29 | 4.29 |
| Reserves | 0.12 | 0.28 | 1.06 | 0.11 | 9.89 | 11.89 | 14.98 |
| 2.27 | 2.31 | 3.24 | 2.14 | 6.16 | 6.17 | 9.17 | |
| 3.85 | 6.88 | 8.71 | 11.47 | 4.82 | 12.81 | 12.91 | |
| Total Liabilities | 6.25 | 9.48 | 13.02 | 16.72 | 25.16 | 35.16 | 41.35 |
| 0.03 | 0.15 | 0.47 | 0.35 | 0.26 | 1.32 | 2.67 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 5.52 | 5.52 |
| 6.22 | 9.33 | 12.55 | 16.35 | 24.88 | 28.32 | 33.16 | |
| Total Assets | 6.25 | 9.48 | 13.02 | 16.72 | 25.16 | 35.16 | 41.35 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| -0.90 | 0.15 | -0.44 | 1.15 | -14.80 | 1.43 | -0.68 | |
| -0.01 | -0.16 | -0.36 | -0.03 | -0.01 | -1.14 | -1.58 | |
| 1.11 | 0.04 | 0.90 | -1.15 | 14.64 | -0.30 | 2.49 | |
| Net Cash Flow | 0.20 | 0.03 | 0.11 | -0.03 | -0.16 | -0.01 | 0.23 |
| Free Cash Flow | -0.91 | -0.01 | -0.80 | 1.14 | -14.81 | 0.28 | -2.26 |
| CFO/OP | -560% | 79% | -32% | 53% | -1,534% | 64% | -2% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 184.22 | 171.06 | 138.73 | 160.87 | 185.72 | 209.50 | 204.23 |
| Inventory Days | 23.71 | 48.88 | 48.05 | 96.71 | 92.25 | 124.85 | 235.14 |
| Days Payable | 174.84 | 206.14 | 165.68 | 211.59 | 69.42 | 209.62 | 237.29 |
| Cash Conversion Cycle | 33.08 | 13.80 | 21.10 | 46.00 | 208.55 | 124.73 | 202.07 |
| Working Capital Days | 69.64 | 47.16 | 47.33 | 62.96 | 210.85 | 148.12 | 201.60 |
| ROCE % | 9.60% | 30.39% | 58.58% | 6.33% | 13.63% | 18.07% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Trade Receivable Turnover Ratio Times |
|
||
| Medical Representatives (MR) Reimbursement Expense INR Lakhs |
|||
| Number of Employees Number |
|||
| Number of Subsidiaries Number |
|||
Extracted by Screener AI
Documents
Announcements
-
Updates
29 May 2026 - Sunrest Lifescience says Annual Secretarial Compliance Report under Regulation 24A is not applicable as an SME-listed company.
-
Updates
29 May 2026 - Confirmed non-applicability of SEBI large corporate debt-raising circular as of 31 March 2026.
-
Outcome of Board Meeting
29 May 2026 - Board approved FY26 audited standalone and consolidated results, appointed VRCA & Associates, and received unmodified audit opinion.
-
Disclosure under SEBI Takeover Regulations
18 May 2026 - Sunrest Lifescience Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, …
-
General Updates
14 May 2026 - Board reconstituted Audit Committee and Stakeholders Relationship Committee effective 14 May 2026.
Business Overview:[1][2]
SLSL is in the business of trading of Pharmaceutical Product on wholesale and retail basis. It provides OTC brands in healthcare & personal care viz. Capsules, Tablets, Syrup, Ointment, Gel, mouthwash, Solution, Suspension, Dry Powders, and Toothpaste